FTC Seeks More Info On $5.2B Watson, Actavis Merger
The competition watchdog's request comes under the Hart–Scott–Rodino Antitrust Improvements Act's notification requirements, and will extend the merger waiting period under the act, Watson said. The tie-up, announced in April, will create the world's third-largest generic pharmaceuticals maker.
"Watson intends to cooperate fully with the FTC's review and...
To view the full article, register now.